Oasmia Pharmaceutical AB
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixi… Read more
Oasmia Pharmaceutical AB (OASMY) - Net Assets
Latest net assets as of September 2025: $133.57 Million USD
Based on the latest financial reports, Oasmia Pharmaceutical AB (OASMY) has net assets worth $133.57 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($150.01 Million) and total liabilities ($16.44 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $133.57 Million |
| % of Total Assets | 89.04% |
| Annual Growth Rate | 8.43% |
| 5-Year Change | -76.95% |
| 10-Year Change | -51.44% |
| Growth Volatility | 52.19 |
Oasmia Pharmaceutical AB - Net Assets Trend (2004–2024)
This chart illustrates how Oasmia Pharmaceutical AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Oasmia Pharmaceutical AB (2004–2024)
The table below shows the annual net assets of Oasmia Pharmaceutical AB from 2004 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $158.33 Million | -19.96% |
| 2023-12-31 | $197.80 Million | -39.22% |
| 2022-12-31 | $325.42 Million | -40.80% |
| 2021-12-31 | $549.71 Million | -19.95% |
| 2020-12-31 | $686.74 Million | -16.19% |
| 2019-12-31 | $819.39 Million | +93.23% |
| 2018-12-31 | $424.05 Million | +22.90% |
| 2017-12-31 | $345.04 Million | +14.87% |
| 2016-12-31 | $300.37 Million | -7.88% |
| 2015-12-31 | $326.05 Million | -13.22% |
| 2014-12-31 | $375.71 Million | +33.27% |
| 2013-12-31 | $281.91 Million | -11.67% |
| 2012-12-31 | $319.15 Million | +16.70% |
| 2011-12-31 | $273.47 Million | -7.04% |
| 2010-12-31 | $294.17 Million | +107.45% |
| 2009-12-31 | $141.80 Million | +131.68% |
| 2008-12-31 | $61.21 Million | -5.56% |
| 2007-12-31 | $64.81 Million | -41.24% |
| 2006-12-31 | $110.30 Million | +87.27% |
| 2005-12-31 | $58.90 Million | +87.58% |
| 2004-12-31 | $31.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oasmia Pharmaceutical AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8238.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $53.80 Million | 33.98% |
| Other Components | $2.03 Billion | 1281.92% |
| Total Equity | $158.33 Million | 100.00% |
Oasmia Pharmaceutical AB Competitors by Market Cap
The table below lists competitors of Oasmia Pharmaceutical AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Matvareexpressen As
OL:MVE
|
$151.42K |
|
AIM5 Ventures Inc
V:AIME-P
|
$151.51K |
|
GRENKELEASING
BE:GLJ
|
$151.57K |
|
BROTHER IND (BI5.SG)
STU:BI5
|
$151.69K |
|
LUMINE GROUP (SUB.VTG.)
F:Z76
|
$151.11K |
|
BANK OF GREECE - Dusseldorf Stock Exchang
DU:BGC
|
$151.06K |
|
STRAX AB SK -03125
F:NOBC
|
$150.99K |
|
ARETTO WELLNESS INC.
F:0RW0
|
$150.79K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oasmia Pharmaceutical AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 197,799,000 to 158,328,000, a change of -39,471,000 (-20.0%).
- Net loss of 39,754,000 reduced equity.
- Other comprehensive income decreased equity by 458,431.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-39.75 Million | -25.11% |
| Other Comprehensive Income | $-458.43K | -0.29% |
| Other Changes | $741.43K | +0.47% |
| Total Change | $- | -19.96% |
Book Value vs Market Value Analysis
This analysis compares Oasmia Pharmaceutical AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.02x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $1.81 | $0.02 | x |
| 2005-12-31 | $3.40 | $0.02 | x |
| 2006-12-31 | $6.27 | $0.02 | x |
| 2007-12-31 | $3.55 | $0.02 | x |
| 2008-12-31 | $3.25 | $0.02 | x |
| 2009-12-31 | $7.08 | $0.02 | x |
| 2010-12-31 | $12.19 | $0.02 | x |
| 2011-12-31 | $9.14 | $0.02 | x |
| 2012-12-31 | $8.64 | $0.02 | x |
| 2013-12-31 | $6.38 | $0.02 | x |
| 2014-12-31 | $7.69 | $0.02 | x |
| 2015-12-31 | $6.33 | $0.02 | x |
| 2016-12-31 | $4.98 | $0.02 | x |
| 2017-12-31 | $4.10 | $0.02 | x |
| 2018-12-31 | $4.33 | $0.02 | x |
| 2019-12-31 | $6.17 | $0.02 | x |
| 2020-12-31 | $-7.89 | $0.02 | x |
| 2021-12-31 | $3.68 | $0.02 | x |
| 2022-12-31 | $1.98 | $0.02 | x |
| 2023-12-31 | $1.10 | $0.02 | x |
| 2024-12-31 | $0.88 | $0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oasmia Pharmaceutical AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -25.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-25.11%) is above the historical average (-27.77%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 7.98% | 22776190.91% | 0.00x | 1.15x | $-634.53K |
| 2005 | -12.41% | -856.40% | 0.01x | 1.08x | $-13.20 Million |
| 2006 | -8.86% | -43.58% | 0.19x | 1.10x | $-20.78 Million |
| 2007 | -7.83% | -7.12% | 0.81x | 1.35x | $-11.54 Million |
| 2008 | -11.63% | -8.95% | 0.82x | 1.59x | $-13.22 Million |
| 2009 | -12.03% | -55.48% | 0.17x | 1.27x | $-31.23 Million |
| 2010 | -22.42% | -62226.42% | 0.00x | 1.09x | $-95.38 Million |
| 2011 | -24.01% | -7370.37% | 0.00x | 1.28x | $-93.02 Million |
| 2012 | -22.68% | 0.00% | 0.00x | 1.39x | $-104.30 Million |
| 2013 | -37.29% | -175186.67% | 0.00x | 1.66x | $-133.30 Million |
| 2014 | -31.27% | -5676.18% | 0.00x | 1.37x | $-155.07 Million |
| 2015 | -43.41% | -2220.92% | 0.01x | 1.58x | $-174.14 Million |
| 2016 | -53.35% | -93164.53% | 0.00x | 1.74x | $-190.28 Million |
| 2017 | -34.20% | -3723.79% | 0.01x | 1.65x | $-152.51 Million |
| 2018 | -40.33% | -8637.37% | 0.00x | 1.52x | $-213.42 Million |
| 2019 | -1.29% | -5.22% | 0.20x | 1.23x | $-92.47 Million |
| 2020 | 0.00% | -5.22% | 0.23x | 0.00x | $111.85 Million |
| 2021 | -25.28% | -530.49% | 0.04x | 1.08x | $-193.92 Million |
| 2022 | -112.79% | -36160.59% | 0.00x | 1.09x | $-399.57 Million |
| 2023 | -65.09% | -1947.07% | 0.03x | 1.12x | $-148.52 Million |
| 2024 | -25.11% | 0.00% | 0.00x | 1.09x | $-55.59 Million |
Industry Comparison
This section compares Oasmia Pharmaceutical AB's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oasmia Pharmaceutical AB (OASMY) | $133.57 Million | 7.98% | 0.12x | $151.35K |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |